(Q37351186)

19 August 2017

Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer (English)

1 reference

19 August 2017

1 reference

2

Janet R Daling

1 reference

19 August 2017

5

Kathleen E Malone

1 reference

19 August 2017

3

Peggy L Porter

1 reference

19 August 2017

4

Mei-Tzu C Tang

1 reference

19 August 2017

Christopher I Li

1

1 reference

PMC publication ID

2745902

19 August 2017

language of work or name

English

0 references

publication date

25 August 2009

1 reference

19 August 2017

1 reference

19 August 2017

69

1 reference

19 August 2017

17

1 reference

19 August 2017

6865-6870

1 reference

Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745902

Concordance of the hormone receptors and correlation of HER-2/neu overexpression of the metachronous cancers of contralateral breasts

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745902

The influence of tamoxifen treatment on the oestrogen receptor in metachronous contralateral breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745902

Epidemiology of contralateral breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745902

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745902

Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745902

Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745902

Heterogeneity in hormone receptor status in primary and metastatic breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745902

Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745902

Tamoxifen stimulates in vivo growth of drug-resistant estrogen receptor-negative breast cancer

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745902

Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745902

Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745902

10.1158/0008-5472.CAN-09-1355

2 September 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference

PMC publication ID

2745902

19 August 2017

PubMed publication ID

19706753

1 reference

PMC publication ID

2745902